Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Oleg K, Glebov"'
Autor:
Anna V. Roschke, Oleg K. Glebov, Samir Lababidi, Kristen S. Gehlhaus, John N. Weinstein, Ilan R. Kirsch
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 10, Iss 11, Pp 1222-1230 (2008)
Chromosomal instability—a hallmark of epithelial cancers—is an ongoing process that results in aneuploidy and karyotypic heterogeneity of a cancer cell population. Previously, we stratified cancer cell lines in the NCI-60 drug discovery panel bas
Externí odkaz:
https://doaj.org/article/704a83da020d4d53be9d5910974efe7c
Autor:
Paul S. Meltzer, Anna V. Roschke, Ilan R. Kirsch, Robert L. Walker, Yoonsoo Park, Ester Rozenblum, Geula Klorin, Frederic J. Kaye, Oleg K. Glebov
Publikováno v:
Cancer Genetics. 206:191-205
High-resolution oligonucleotide array comparative genomic hybridization (aCGH) and spectral karyotyping (SKY) were applied to a panel of malignant mesothelioma (MMt) cell lines. SKY has not been applied to MMt before, and complete karyotypes are repo
Autor:
P. Leif Bergsagel, Yulia N. Demchenko, W. Michael Kuehl, Jonathan J Keats, Oleg K. Glebov, Adriana Zingone
Publikováno v:
Blood. 115:3541-3552
Mutations involving the nuclear factor-κB (NF-κB) pathway are present in at least 17% of multiple myeloma (MM) tumors and 40% of MM cell lines (MMCLs). These mutations, which are apparent progression events, enable MM tumors to become less dependen
Publikováno v:
DNA Repair. 8:330-335
The Karpas-620 human myeloma cell line (HMCL) expresses high levels of Cyclin D1 (CCND1), but has a der(8)t(8;11) and a der(14)t(8;14), and not a conventional t(11;14). Fluorescent in situ hybridization (FISH) and array comparative genomic hybridizat
Autor:
Samir Lababidi, John N. Weinstein, Kristen Gehlhaus, Oleg K. Glebov, Anna V. Roschke, Ilan R. Kirsch
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 10, Iss 11, Pp 1222-1230 (2008)
Chromosomal instability—a hallmark of epithelial cancers—is an ongoing process that results in aneuploidy and karyotypic heterogeneity of a cancer cell population. Previously, we stratified cancer cell lines in the NCI-60 drug discovery panel bas
Autor:
Ilan R. Kirsch, Kenneth Nakahara, Oleg K. Glebov, Peter W. Soballe, John Denobile, Luz Rodriguez, Janet Cliatt
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 15:2253-2262
Aberrant crypt foci (ACF) are considered the earliest identifiable preneoplastic colonic lesions; thus, a greater understanding of the nature of genetic changes underlying the transformation of normal colonic mucosa (NM) into ACF may provide insight
Publikováno v:
Proceedings of the National Academy of Sciences. 103:15359-15363
Mismatch repair (MMR) is critical to maintaining the integrity of the genome, and deficiencies in MMR are correlated with cancerous transformations. Bulky rhodium intercalators target DNA base mismatches with high specificity. Here we describe the ap
Publikováno v:
Journal of the National Cancer Institute. Monographs. (39)
Translocations involving an MYC gene (c >> N >>L) are very late tumor progression events and provide a paradigm for secondary translocations in multiple myeloma. Using a combination of fluorescent in situ hybridization and comparative genomic hybridi
Publikováno v:
Best practiceresearch. Clinical haematology. 20(4)
The genetics of myeloma has been increasingly elucidated in recent years. Recurrent genetic events, and also biologically distinct and clinically relevant genetic subtypes of myeloma have been defined. This has facilitated our understanding of the mo
Autor:
Casey Jo Humbyrd, Gary Gordon, Jean Jenkins, Steven Gallinger, Oleg K. Glebov, Aby Buchbinder, Luz Rodriguez, Henry T. Lynch, Ilan R. Kirsch, Kenneth Nakahara, Janet Cliatt, Patrick M. Lynch, John Denobile, Sherri Patterson, Peter W. Soballe, Ernest T. Hawk
Publikováno v:
Cancer epidemiology, biomarkersprevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 15(7)
A clinical trial was recently conducted to evaluate the safety and efficacy of a selective inhibitor of cyclooxygenase-2 (celecoxib) in hereditary nonpolyposis colon cancer patients. In a randomized, placebo-controlled phase I/II multicenter trial, h